Barchart on MSN
DexCom Earnings Preview: What to Expect
Valued at a market cap of $25.5 billion, DexCom, Inc. (DXCM) is a medical device company that designs, develops, and ...
TipRanks on MSN
DexCom price target lowered to $85 from $105 at Citi
Citi lowered the firm’s price target on DexCom (DXCM) to $85 from $105 and keeps a Buy rating on the shares. The firm is cautious on medical ...
Medtech leaders with varying degrees of experience have offered a range of advice in terms of leadership at the helm of a ...
DexCom showed strong growth, margin expansion, and Stelo's OTC launch unlocked new markets despite competitive and regulatory ...
Continuous glucose monitors (CGMs) are wearable technologies that track blood sugar in real time and help patients with type 2 diabetes improve blood sugar control.
Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...
Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring ...
Investing.com -- DexCom (NASDAQ:DXCM) stock fell 3% Thursday after Hunterbrook Media published a scathing short report alleging serious safety issues with the company’s G7 continuous glucose ...
At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...
DexCom announced that Chairman and CEO Kevin R. Sayer has taken a temporary medical leave as of September 14, 2025, with President and COO Jacob S. Leach appointed interim CEO and Mark Foletta as ...
Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...
Next presentation this afternoon is from DexCom, a leader in developing and commercializing continuous glucose monitoring systems for people with diabetes and I'm sure in the future beyond diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results